bimatoprost 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
prostaglandins 371 155206-00-1

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • lumigan
  • bimatoprost
  • prostamide
A cloprostenol-derived amide that is used as an ANTIHYPERTENSIVE AGENT in the treatment of OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION.
  • Molecular weight: 415.57
  • Formula: C25H37NO4
  • CLOGP: 1.75
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 4
  • TPSA: 89.79
  • ALOGS: -4.35
  • ROTB: 12
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.80 mg/mL Benet LZ, Broccatelli F, Oprea TI
Vd (Volume of distribution) 0.67 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 25 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.12 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 0.45 hours Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2A,ACVR2B,AXL,BRAF,BTK,CAMK2D,CDK5,CDK9,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,GRK2,ITK,MAP3K21,MAPK7,NTRK2,PDK1,PDK2,PDK4,PIK3CB,PRKDC,SIK2,SYK,TEK,TGFBR1,ZAP70 28
kinase-selectivity-class AXL,GRK2,MAP2K6 3
pfas-class PFAS structural alert (1 = True, 0 = False) 0

Approvals:

DateAgencyCompanyOrphan
March 8, 2002 EMA
March 16, 2001 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Ocular hyperaemia 2351.89 16.79 649 16924 33149 90577725
Eye irritation 1831.99 16.79 535 17038 33443 90577431
Madarosis 1777.74 16.79 342 17231 3287 90607587
Erythema of eyelid 1742.76 16.79 331 17242 2952 90607922
Eye pruritus 1328.42 16.79 403 17170 28624 90582250
Eyelids pruritus 935.98 16.79 181 17392 1783 90609091
Eyelid irritation 702.67 16.79 128 17445 880 90609994
Eye swelling 616.56 16.79 227 17346 29159 90581715
Eyelid oedema 586.70 16.79 174 17399 11360 90599514
Eye pain 408.40 16.79 190 17383 43978 90566896
Intraocular pressure increased 386.91 16.79 113 17460 6980 90603894
Treatment failure 362.20 16.79 365 17208 303563 90307311
Blepharal pigmentation 312.74 16.79 45 17528 37 90610837
Trichorrhexis 250.02 16.79 58 17515 1429 90609445
Skin hyperpigmentation 237.10 16.79 77 17496 6774 90604100
Vision blurred 231.99 16.79 183 17390 110110 90500764
Dry eye 224.90 16.79 140 17433 57791 90553083
Eye discharge 219.12 16.79 76 17497 8182 90602692
Lacrimation increased 206.17 16.79 102 17471 26960 90583914
Drug ineffective 181.48 16.79 632 16941 1383666 89227208
Blepharitis 163.63 16.79 51 17522 3925 90606949
Scleral hyperaemia 162.11 16.79 31 17542 285 90610589
Eyelid pain 161.06 16.79 36 17537 747 90610127
Growth of eyelashes 158.41 16.79 29 17544 205 90610669
Wrong technique in product usage process 142.35 16.79 115 17458 71456 90539418
Product administered at inappropriate site 140.97 16.79 46 17527 4105 90606769
Eyelid exfoliation 137.81 16.79 27 17546 285 90610589
Inappropriate schedule of product administration 125.62 16.79 150 17423 149783 90461091
Eyelash discolouration 121.59 16.79 20 17553 67 90610807
Swelling of eyelid 121.15 16.79 44 17529 5410 90605464
Visual acuity reduced 120.71 16.79 68 17505 23342 90587532
Corneal endothelial cell loss 119.85 16.79 17 17556 11 90610863
Iris hyperpigmentation 111.79 16.79 17 17556 28 90610846
Foreign body sensation in eyes 105.74 16.79 35 17538 3265 90607609
Eyelid thickening 99.64 16.79 17 17556 75 90610799
Corneal oedema 97.99 16.79 29 17544 1872 90609002
Erythema 94.96 16.79 164 17409 229082 90381792
Ocular discomfort 86.67 16.79 36 17537 6334 90604540
Abnormal sensation in eye 79.92 16.79 25 17548 1946 90608928
Eye colour change 74.30 16.79 17 17556 393 90610481
Eyelid rash 73.89 16.79 17 17556 403 90610471
Hypersensitivity 72.63 16.79 223 17350 454454 90156420
Lid sulcus deepened 70.27 16.79 13 17560 98 90610776
Corneal opacity 70.07 16.79 19 17554 892 90609982
Skin irritation 68.73 16.79 39 17534 13564 90597310
Dark circles under eyes 67.20 16.79 17 17556 607 90610267
Glaucoma 65.31 16.79 44 17529 20711 90590163
Hair growth abnormal 64.67 16.79 25 17548 3651 90607223
Skin discolouration 63.34 16.79 59 17514 44256 90566618
Product packaging quantity issue 59.48 16.79 19 17554 1583 90609291
Expired product administered 58.42 16.79 28 17545 6894 90603980
Hordeolum 57.83 16.79 25 17548 4853 90606021
Eyelid margin crusting 57.60 16.79 19 17554 1753 90609121
Maternal exposure during pregnancy 57.50 16.79 3 17570 360060 90250814
Eyelid disorder 57.36 16.79 20 17553 2183 90608691
Product delivery mechanism issue 55.28 16.79 14 17559 502 90610372
Iris disorder 54.46 16.79 10 17563 72 90610802
Eye inflammation 52.18 16.79 27 17546 7824 90603050
Systemic lupus erythematosus 52.09 16.79 5 17568 361891 90248983
Cataract 52.06 16.79 67 17506 72025 90538849
Incorrect dose administered 51.81 16.79 70 17503 78860 90532014
Glossodynia 50.39 16.79 3 17570 321776 90289098
Eye disorder 50.20 16.79 42 17531 27348 90583526
Eyelash changes 49.68 16.79 7 17566 4 90610870
Joint swelling 49.34 16.79 18 17555 503282 90107592
Eye infection 49.16 16.79 32 17541 14222 90596652
Ocular surface disease 48.52 16.79 9 17564 69 90610805
Cystoid macular oedema 46.85 16.79 17 17556 2083 90608791
Conjunctivitis 44.96 16.79 39 17534 26667 90584207
Infusion related reaction 44.19 16.79 13 17560 416767 90194107
Eyelid skin dryness 44.08 16.79 12 17561 572 90610302
Iritis 44.05 16.79 19 17554 3667 90607207
Visual impairment 42.55 16.79 85 17488 132280 90478594
Photophobia 41.87 16.79 34 17539 21235 90589639
Body height decreased 41.64 16.79 27 17546 11922 90598952
Conjunctival hyperaemia 40.07 16.79 17 17556 3152 90607722
Wound 39.14 16.79 6 17567 302974 90307900
Intraocular pressure decreased 38.55 16.79 8 17565 115 90610759
Eye allergy 38.37 16.79 13 17560 1302 90609572
Pericarditis 38.16 16.79 4 17569 270147 90340727
Conjunctival scar 38.05 16.79 7 17566 51 90610823
Periorbital fat atrophy 37.74 16.79 5 17568 0 90610874
Eyelash hyperpigmentation 37.74 16.79 5 17568 0 90610874
Prostaglandin analogue periorbitopathy 37.74 16.79 5 17568 0 90610874
Condition aggravated 37.70 16.79 36 17537 595509 90015365
Contraindicated product administered 35.78 16.79 9 17564 320130 90290744
Product container issue 35.42 16.79 14 17559 2167 90608707
Asthenopia 34.76 16.79 15 17558 2899 90607975
Therapeutic product effect decreased 34.72 16.79 6 17567 277565 90333309
Lentigo maligna 34.71 16.79 9 17564 355 90610519
Arthropathy 34.37 16.79 14 17559 366228 90244646
Application site discolouration 34.31 16.79 11 17562 927 90609947
General physical health deterioration 34.27 16.79 13 17560 355102 90255772
Intraocular pressure test abnormal 33.63 16.79 8 17565 220 90610654
Application site pain 33.59 16.79 17 17556 4703 90606171
Pyrexia 33.15 16.79 48 17525 660437 89950437
Eyelid sensory disorder 32.97 16.79 7 17566 113 90610761
Trichiasis 32.69 16.79 7 17566 118 90610756
Scleral discolouration 32.60 16.79 9 17564 452 90610422
Exposure during pregnancy 32.49 16.79 4 17569 238406 90372468
Application site pruritus 32.30 16.79 16 17557 4231 90606643
Hyperplastic cholecystopathy 30.79 16.79 7 17566 157 90610717
Drug intolerance 30.78 16.79 25 17548 447566 90163308
Eyelid vascular disorder 30.19 16.79 4 17569 0 90610874
Mobility decreased 30.12 16.79 6 17567 250728 90360146
Visual field defect 29.50 16.79 18 17555 7148 90603726
Application site erythema 29.22 16.79 16 17557 5192 90605682
Hepatic enzyme increased 28.98 16.79 17 17556 360719 90250155
Alopecia 28.96 16.79 32 17541 495039 90115835
Implantation complication 28.63 16.79 5 17568 26 90610848
Product quality issue 27.99 16.79 53 17520 79272 90531602
Malignant melanoma of eyelid 27.96 16.79 4 17569 3 90610871
Injury 27.66 16.79 3 17570 197346 90413528
Toxicity to various agents 27.01 16.79 11 17562 287835 90323039
Accidental exposure to product 26.92 16.79 37 17536 42329 90568545
Fibromyalgia 26.82 16.79 4 17569 206265 90404609
Application site irritation 26.40 16.79 11 17562 1950 90608924
Periorbital disorder 26.34 16.79 5 17568 44 90610830
Lower respiratory tract infection 26.22 16.79 8 17565 250651 90360223
Impaired healing 25.37 16.79 7 17566 234192 90376682
Therapeutic product effect incomplete 24.67 16.79 4 17569 193892 90416982
Macular oedema 24.59 16.79 14 17559 4895 90605979
Psoriatic arthropathy 24.40 16.79 7 17566 228328 90382546
Product container seal issue 24.14 16.79 6 17567 199 90610675
Punctate keratitis 23.74 16.79 8 17565 788 90610086
Discomfort 23.37 16.79 12 17561 274323 90336551
Trabeculoplasty 22.65 16.79 3 17570 0 90610874
Dermatochalasis 22.01 16.79 4 17569 27 90610847
Product odour abnormal 21.78 16.79 9 17564 1562 90609312
Sleep disorder 21.29 16.79 6 17567 198024 90412850
Eyelid ptosis 21.19 16.79 16 17557 8990 90601884
Product use issue 20.77 16.79 20 17553 329899 90280975
Gastrointestinal disorder 20.74 16.79 12 17561 256675 90354199
Overdose 20.64 16.79 3 17570 157706 90453168
Ulcerative keratitis 20.46 16.79 11 17562 3442 90607432
Arthralgia 20.30 16.79 80 17493 778442 89832432
Milia 20.29 16.79 5 17568 160 90610714
Meibomianitis 19.87 16.79 4 17569 49 90610825
Hypoaesthesia 19.84 16.79 19 17554 314191 90296683
Thrombocytopenia 19.53 16.79 8 17565 208717 90402157
Flat anterior chamber of eye 19.37 16.79 4 17569 56 90610818
Enophthalmos 19.37 16.79 4 17569 56 90610818
Breast inflammation 19.36 16.79 5 17568 194 90610680
Pain 19.24 16.79 114 17459 996227 89614647
Corneal decompensation 19.05 16.79 4 17569 61 90610813
Instillation site pain 18.79 16.79 7 17566 923 90609951
Uveitis 18.64 16.79 19 17554 15884 90594990
Product physical consistency issue 18.62 16.79 7 17566 947 90609927
C-reactive protein increased 18.59 16.79 6 17567 181383 90429491
Breast haemorrhage 18.54 16.79 5 17568 230 90610644
Eyelash thickening 18.49 16.79 3 17570 9 90610865
Inflammatory carcinoma of the breast 18.48 16.79 4 17569 71 90610803
Reaction to preservatives 18.45 16.79 5 17568 234 90610640
Infection 18.44 16.79 26 17547 362068 90248806
Burning sensation 18.32 16.79 39 17534 63413 90547461
Therapeutic response decreased 18.14 16.79 48 17525 89681 90521193
Ocular vascular disorder 17.49 16.79 6 17567 624 90610250
Ill-defined disorder 17.44 16.79 7 17566 184884 90425990
Endophthalmitis 17.35 16.79 11 17562 4674 90606200
Open angle glaucoma 17.17 16.79 5 17568 305 90610569
Stomatitis 16.89 16.79 17 17556 274681 90336193
Foot amputation 16.80 16.79 5 17568 329 90610545

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Treatment failure 477.73 16.44 221 6544 62403 42552167
Intraocular pressure increased 369.40 16.44 102 6663 6331 42608239
Eye irritation 166.76 16.44 64 6701 11254 42603316
Ocular hyperaemia 151.99 16.44 66 6699 15897 42598673
Eye pain 104.64 16.44 52 6713 16978 42597592
Visual acuity reduced 97.33 16.44 50 6715 17500 42597070
Vision blurred 71.76 16.44 63 6702 53636 42560934
Glaucoma 62.21 16.44 29 6736 8219 42606351
Corneal oedema 59.56 16.44 18 6747 1530 42613040
Corneal opacity 59.47 16.44 15 6750 650 42613920
Enophthalmos 58.11 16.44 8 6757 5 42614565
Growth of eyelashes 54.99 16.44 10 6755 85 42614485
Corneal endothelial cell loss 54.24 16.44 7 6758 0 42614570
Cataract 53.56 16.44 42 6723 30562 42584008
Conjunctival hyperaemia 50.49 16.44 19 6746 3157 42611413
Open angle glaucoma 44.43 16.44 10 6755 264 42614306
Blepharal pigmentation 44.06 16.44 6 6759 3 42614567
Choroidal detachment 42.50 16.44 11 6754 529 42614041
Scleral hyperaemia 37.75 16.44 7 6758 67 42614503
Visual field defect 36.11 16.44 17 6748 4921 42609649
Eye pruritus 34.78 16.44 22 6743 11390 42603180
Fat tissue decreased 34.67 16.44 7 6758 108 42614462
Foreign body sensation in eyes 32.05 16.44 10 6755 945 42613625
Macular oedema 31.48 16.44 14 6751 3555 42611015
Erythema of eyelid 31.39 16.44 11 6754 1492 42613078
Implantation complication 30.90 16.44 5 6760 19 42614551
Blindness 30.00 16.44 24 6741 17954 42596616
Punctate keratitis 29.99 16.44 8 6757 433 42614137
Cardioactive drug level increased 29.83 16.44 11 6754 1726 42612844
Eye inflammation 29.60 16.44 13 6752 3205 42611365
Iritis 29.56 16.44 11 6754 1771 42612799
Instillation site pain 29.51 16.44 6 6759 96 42614474
Ocular surface disease 28.79 16.44 6 6759 109 42614461
Lacrimation increased 26.98 16.44 19 6746 11739 42602831
Product administered at inappropriate site 26.84 16.44 12 6753 3086 42611484
Dry eye 26.51 16.44 21 6744 15485 42599085
Corneal infiltrates 26.21 16.44 6 6759 171 42614399
Visual impairment 25.81 16.44 33 6732 43080 42571490
Corneal neovascularisation 24.89 16.44 5 6760 75 42614495
Iridocyclitis 23.86 16.44 10 6755 2201 42612369
Intraocular pressure fluctuation 23.83 16.44 4 6761 20 42614550
Keratitis interstitial 23.83 16.44 4 6761 20 42614550
Lid sulcus deepened 23.35 16.44 5 6760 104 42614466
Complication of device insertion 22.71 16.44 5 6760 119 42614451
Corneal erosion 22.59 16.44 5 6760 122 42614448
Blepharitis 21.72 16.44 9 6756 1924 42612646
Eyelid irritation 21.33 16.44 6 6759 396 42614174
Corneal pigmentation 21.17 16.44 3 6762 3 42614567
Product packaging quantity issue 21.16 16.44 8 6757 1345 42613225
Ulcerative keratitis 21.05 16.44 9 6756 2079 42612491
Product container issue 20.28 16.44 7 6758 907 42613663
Eye swelling 20.07 16.44 16 6749 11904 42602666
Corneal disorder 19.28 16.44 7 6758 1052 42613518
Uveitis 19.04 16.44 14 6751 9244 42605326
Computerised tomogram head abnormal 18.78 16.44 4 6761 81 42614489
Photophobia 18.35 16.44 13 6752 8106 42606464
Eye disorder 18.31 16.44 15 6750 11597 42602973
Intraocular pressure decreased 18.26 16.44 4 6761 93 42614477
Visual acuity tests abnormal 18.26 16.44 4 6761 93 42614477
Eye opacity 18.23 16.44 3 6762 13 42614557
Iris atrophy 18.22 16.44 4 6761 94 42614476
Blood pressure systolic increased 17.68 16.44 22 6743 27946 42586624
Meibomian gland dysfunction 17.51 16.44 4 6761 113 42614457
Abnormal sensation in eye 17.40 16.44 6 6759 775 42613795
Skin hypopigmentation 16.84 16.44 5 6760 400 42614170
Ocular pemphigoid 16.82 16.44 4 6761 135 42614435

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Ocular hyperaemia 1228.10 14.90 387 16845 38899 110533168
Eye irritation 1063.84 14.90 334 16898 33118 110538949
Erythema of eyelid 983.54 14.90 204 17028 3711 110568356
Madarosis 752.02 14.90 160 17072 3303 110568764
Eye pruritus 644.67 14.90 228 17004 32547 110539520
Eyelids pruritus 571.70 14.90 114 17118 1683 110570384
Intraocular pressure increased 449.46 14.90 133 17099 10743 110561324
Eyelid irritation 397.58 14.90 78 17154 1053 110571014
Eyelid oedema 381.02 14.90 127 17105 15135 110556932
Eye swelling 318.16 14.90 137 17095 32911 110539156
Eye pain 278.26 14.90 142 17090 49957 110522110
Blepharal pigmentation 215.97 14.90 30 17202 23 110572044
Vision blurred 198.83 14.90 163 17069 128859 110443208
Visual acuity reduced 163.64 14.90 86 17146 32087 110539980
Lacrimation increased 144.08 14.90 78 17154 30872 110541195
Growth of eyelashes 142.61 14.90 25 17207 172 110571895
Dry eye 141.08 14.90 95 17137 55698 110516369
Skin hyperpigmentation 135.46 14.90 51 17181 8645 110563422
Trichorrhexis 129.68 14.90 30 17202 915 110571152
Blepharitis 114.03 14.90 38 17194 4514 110567553
Eye discharge 113.75 14.90 45 17187 8709 110563358
Scleral hyperaemia 111.56 14.90 22 17210 305 110571762
Product administered at inappropriate site 96.40 14.90 35 17197 5358 110566709
Eyelid exfoliation 88.23 14.90 18 17214 299 110571768
Glaucoma 83.76 14.90 49 17183 22468 110549599
Eyelid pain 82.48 14.90 20 17212 749 110571318
Ocular surface disease 78.93 14.90 15 17217 169 110571898
Conjunctival hyperaemia 75.85 14.90 30 17202 5801 110566266
Corneal oedema 73.59 14.90 25 17207 3148 110568919
Iris hyperpigmentation 73.03 14.90 11 17221 23 110572044
Cataract 72.57 14.90 75 17157 79410 110492657
Foreign body sensation in eyes 72.38 14.90 25 17207 3309 110568758
Wrong technique in product usage process 71.91 14.90 78 17154 87270 110484797
Abnormal sensation in eye 70.05 14.90 22 17210 2164 110569903
Corneal opacity 68.22 14.90 19 17213 1232 110570835
Eyelash discolouration 67.08 14.90 12 17220 94 110571973
Enophthalmos 64.05 14.90 11 17221 66 110572001
Open angle glaucoma 61.93 14.90 15 17217 559 110571508
Body height decreased 61.68 14.90 31 17201 10532 110561535
Eyelid thickening 56.64 14.90 10 17222 72 110571995
Corneal endothelial cell loss 55.22 14.90 8 17224 11 110572056
Visual field defect 54.27 14.90 28 17204 10044 110562023
Inappropriate schedule of product administration 53.74 14.90 106 17126 203531 110368536
Ocular discomfort 52.65 14.90 26 17206 8507 110563560
Erythema 52.35 14.90 130 17102 291317 110280750
Iritis 47.09 14.90 20 17212 4632 110567435
Macular oedema 45.30 14.90 22 17210 6944 110565123
Eye inflammation 45.15 14.90 24 17208 9147 110562920
Eyelid disorder 44.45 14.90 16 17216 2389 110569678
Implantation complication 43.52 14.90 7 17225 26 110572041
Choroidal detachment 43.36 14.90 12 17220 760 110571307
Fat tissue decreased 42.07 14.90 9 17223 190 110571877
Lid sulcus deepened 41.50 14.90 9 17223 203 110571864
Swelling of eyelid 40.24 14.90 20 17212 6633 110565434
Ulcerative keratitis 40.13 14.90 18 17214 4748 110567319
Hair growth abnormal 38.45 14.90 16 17216 3521 110568546
Punctate keratitis 38.09 14.90 12 17220 1192 110570875
Eye colour change 38.07 14.90 10 17222 519 110571548
Periorbital disorder 37.78 14.90 7 17225 68 110571999
Conjunctival scar 36.96 14.90 9 17223 343 110571724
Conjunctivitis 36.59 14.90 35 17197 33757 110538310
Blindness 36.26 14.90 36 17196 36323 110535744
Prostaglandin analogue periorbitopathy 33.69 14.90 5 17227 9 110572058
Eye infection 32.62 14.90 23 17209 14495 110557572
Skin irritation 32.43 14.90 24 17208 16295 110555772
Photophobia 32.37 14.90 29 17203 25742 110546325
Lentigo maligna 31.06 14.90 9 17223 673 110571394
Skin discolouration 30.62 14.90 38 17194 49008 110523059
Fall 30.47 14.90 179 17053 603303 109968764
Instillation site pain 30.26 14.90 9 17223 737 110571330
Hyperplastic cholecystopathy 29.87 14.90 7 17225 226 110571841
Visual impairment 29.61 14.90 65 17167 134363 110437704
Eyelid margin crusting 28.43 14.90 11 17221 2005 110570062
Uveitis 28.40 14.90 25 17207 21685 110550382
Treatment failure 27.46 14.90 5 17227 277229 110294838
Product container issue 27.29 14.90 10 17222 1570 110570497
Drug ineffective 26.72 14.90 357 16875 1520183 109051884
Flat anterior chamber of eye 26.53 14.90 6 17226 165 110571902
Intraocular pressure decreased 25.87 14.90 6 17226 185 110571882
Expired product administered 25.51 14.90 16 17216 8304 110563763
Eyelash thickening 25.28 14.90 4 17228 13 110572054
Iris disorder 25.03 14.90 6 17226 214 110571853
Cystoid macular oedema 24.94 14.90 11 17221 2789 110569278
Corneal erosion 24.86 14.90 7 17225 472 110571595
Toxicity to various agents 24.81 14.90 23 17209 480532 110091535
Dark circles under eyes 24.07 14.90 7 17225 530 110571537
Intraocular pressure fluctuation 23.87 14.90 5 17227 95 110571972
Eyelid sensory disorder 23.68 14.90 5 17227 99 110571968
Asthenopia 23.65 14.90 11 17221 3153 110568914
General physical health deterioration 23.60 14.90 19 17213 425276 110146791
Eyelash hyperpigmentation 23.30 14.90 3 17229 0 110572067
Eyelid vascular disorder 23.30 14.90 3 17229 0 110572067
Periorbital fat atrophy 23.30 14.90 3 17229 0 110572067
Application site discolouration 23.29 14.90 8 17224 1041 110571026
Eyelid ptosis 22.96 14.90 18 17214 13309 110558758
Therapeutic product effect decreased 22.95 14.90 5 17227 244311 110327756
Eye haemorrhage 22.69 14.90 17 17215 11757 110560310
Corneal disorder 22.48 14.90 10 17222 2587 110569480
Infusion related reaction 22.46 14.90 16 17216 381146 110190921
Keratitis interstitial 22.40 14.90 4 17228 31 110572036
Mobility decreased 22.02 14.90 5 17227 237417 110334650
Corneal infiltrates 21.99 14.90 6 17226 360 110571707
Glossodynia 21.99 14.90 4 17228 222000 110350067
Trichiasis 21.99 14.90 5 17227 141 110571926
Joint swelling 21.92 14.90 22 17210 442823 110129244
Cataract subcapsular 21.85 14.90 8 17224 1253 110570814
Drug intolerance 21.52 14.90 19 17213 406493 110165574
Cardioactive drug level increased 21.52 14.90 11 17221 3871 110568196
Malignant melanoma of eyelid 21.22 14.90 3 17229 3 110572064
Visual acuity tests abnormal 20.97 14.90 5 17227 174 110571893
Condition aggravated 20.79 14.90 53 17179 734783 109837284
Eye disorder 20.67 14.90 24 17208 28882 110543185
Eyelid rash 20.43 14.90 6 17226 470 110571597
Corneal neovascularisation 20.06 14.90 5 17227 210 110571857
Intraocular pressure test abnormal 19.93 14.90 5 17227 216 110571851
Angle closure glaucoma 19.64 14.90 10 17222 3489 110568578
Pericarditis 19.56 14.90 5 17227 219109 110352958
Alopecia 19.36 14.90 17 17215 364736 110207331
Hordeolum 19.11 14.90 11 17221 4890 110567177
Reaction to preservatives 18.97 14.90 5 17227 263 110571804
Meibomianitis 18.67 14.90 4 17228 85 110571982
Incorrect dose administered 18.33 14.90 46 17186 103595 110468472
Extrasystoles 18.27 14.90 13 17219 8305 110563762
Meibomian gland dysfunction 18.12 14.90 5 17227 313 110571754
Application site pruritus 18.01 14.90 10 17222 4150 110567917
Wound 17.99 14.90 7 17225 234430 110337637
Macular fibrosis 17.96 14.90 6 17226 718 110571349
Anterior chamber inflammation 17.56 14.90 6 17226 769 110571298
Instillation site reaction 17.55 14.90 5 17227 352 110571715
Computerised tomogram head abnormal 17.38 14.90 4 17228 119 110571948
Eye opacity 17.19 14.90 3 17229 20 110572047
Fibromyalgia 17.10 14.90 3 17229 170906 110401161
Choroidal effusion 16.74 14.90 6 17226 884 110571183
Exposure during pregnancy 16.62 14.90 3 17229 167421 110404646
Arcus lipoides 16.60 14.90 3 17229 25 110572042
Contraindicated product administered 16.59 14.90 9 17223 248258 110323809
Blindness unilateral 16.39 14.90 13 17219 9773 110562294
Inflammatory carcinoma of the breast 16.30 14.90 3 17229 28 110572039
Endophthalmitis 16.18 14.90 12 17220 8175 110563892
Product dose omission issue 15.91 14.90 95 17137 321687 110250380
Type 2 diabetes mellitus 15.90 14.90 4 17228 177228 110394839
Product packaging quantity issue 15.81 14.90 7 17225 1792 110570275
Hepatic enzyme increased 15.80 14.90 16 17216 320876 110251191
Breast inflammation 15.80 14.90 4 17228 179 110571888
Eye allergy 15.73 14.90 6 17226 1053 110571014
Eosinophil count 15.63 14.90 4 17228 187 110571880
Thrombocytopenia 15.43 14.90 19 17213 348866 110223201
Breast haemorrhage 15.35 14.90 4 17228 201 110571866

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC S01EE03 SENSORY ORGANS
OPHTHALMOLOGICALS
ANTIGLAUCOMA PREPARATIONS AND MIOTICS
Prostaglandin analogues
FDA CS M0017805 Prostaglandins
FDA EPC N0000175454 Prostaglandin Analog
MeSH PA D000959 Antihypertensive Agents
MeSH PA D002317 Cardiovascular Agents
CHEBI has role CHEBI:35674 antihypertensive agent
CHEBI has role CHEBI:39456 antiglaucoma drug

Related Drugs by ATC class:

S01EE Prostaglandin analogues 6 drugs
dorzolamidelatanoprostlatanoprostene bunodnetarsudiltafluprosttravoprost

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Ocular hypertension indication 4210003 DOID:9282
Hypertrichosis of eyelid indication 79830009 DOID:11669
Open-angle glaucoma indication 84494001 DOID:1067
Aphakia contraindication 24010005
Macular retinal edema contraindication 37231002 DOID:4449
Iritis contraindication 65074000 DOID:1406
Pseudophakia contraindication 95217000
Uveitis contraindication 128473001 DOID:13141
Liver function tests abnormal contraindication 166603001
Cystoid macular edema contraindication 193387007 DOID:4447
Disease of liver contraindication 235856003 DOID:409




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 13.89 acidic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
10MCG DURYSTA ABBVIE N211911 March 4, 2020 RX IMPLANT OPHTHALMIC 8206737 April 7, 2027 REDUCTION OF INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH OPEN ANGLE GLAUCOMA(OAG) OR OCULAR HYPERTENSION (OHT) WITH A BIODEGRADABLE BIMATOPROST IMPLANT
10MCG DURYSTA ABBVIE N211911 March 4, 2020 RX IMPLANT OPHTHALMIC 9980974 Oct. 31, 2034 REDUCTION OF INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH OPEN ANGLE GLAUCOMA(OAG) OR OCULAR HYPERTENSION (OHT) WITH A BIODEGRADABLE BIMATOPROST IMPLANT
0.01% ZOLYMBUS THEA PHARMA N217307 Sept. 9, 2025 RX GEL OPHTHALMIC 10314780 June 8, 2036 A METHOD OF TREATING A PATIENT WITH GLAUCOMA OR OCULAR HYPERTENSION

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
0.01% ZOLYMBUS THEA PHARMA N217307 Sept. 9, 2025 RX GEL OPHTHALMIC Sept. 9, 2028 NEW DOSAGE FORM

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Prostaglandin F2-alpha receptor GPCR AGONIST Ki 5.30 WOMBAT-PK CHEMBL
Aldo-keto reductase family 1 member C3 Enzyme IC50 5.30 CHEMBL

External reference:

IDSource
D02724 KEGG_DRUG
283810 RXNORM
C0937917 UMLSCUI
CHEBI:51230 CHEBI
15M PDB_CHEM_ID
CHEMBL1200963 ChEMBL_ID
D000069580 MESH_DESCRIPTOR_UI
DB00905 DRUGBANK_ID
5311027 PUBCHEM_CID
1958 IUPHAR_LIGAND_ID
8035 INN_ID
QXS94885MZ UNII
15937 MMSL
234008 MMSL
41256 MMSL
129492005 SNOMEDCT_US
395300006 SNOMEDCT_US
4021262 VANDF
009115 NDDF
QXS94885MZ INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
LUMIGAN HUMAN PRESCRIPTION DRUG LABEL 1 0023-3205 SOLUTION/ DROPS 0.10 mg OPHTHALMIC NDA 25 sections
LUMIGAN HUMAN PRESCRIPTION DRUG LABEL 1 0023-3205 SOLUTION/ DROPS 0.10 mg OPHTHALMIC NDA 25 sections
LATISSE HUMAN PRESCRIPTION DRUG LABEL 1 0023-3616 SOLUTION/ DROPS 0.30 mg OPHTHALMIC NDA 25 sections
LUMIGAN HUMAN PRESCRIPTION DRUG LABEL 1 0023-9187 SOLUTION/ DROPS 0.30 mg OPHTHALMIC Export only 1 sections
DURYSTA HUMAN PRESCRIPTION DRUG LABEL 1 0023-9652 IMPLANT 10 ug INTRACAMERAL NDA 24 sections
Bimatoprost HUMAN PRESCRIPTION DRUG LABEL 1 0781-6206 SOLUTION/ DROPS 0.30 mg OPHTHALMIC ANDA 23 sections
BIMATOPROST HUMAN PRESCRIPTION DRUG LABEL 1 42571-128 SOLUTION/ DROPS 0.30 mg OPHTHALMIC ANDA 24 sections
Bimatoprost Human Prescription Drug Label 1 46708-507 SOLUTION/ DROPS 0.30 mg OPHTHALMIC ANDA 23 sections
bimatoprost Human Prescription Drug Label 1 46708-511 SOLUTION/ DROPS 0.30 mg OPHTHALMIC ANDA 22 sections
Bimatoprost HUMAN PRESCRIPTION DRUG LABEL 1 50383-908 SOLUTION/ DROPS 0.30 mg OPHTHALMIC ANDA 23 sections
Bimatoprost HUMAN PRESCRIPTION DRUG LABEL 1 50383-912 SOLUTION 3 ug TOPICAL ANDA 22 sections
LUMIGAN HUMAN PRESCRIPTION DRUG LABEL 1 54868-4575 SOLUTION/ DROPS 0.30 mg OPHTHALMIC NDA 25 sections
LUMIGAN HUMAN PRESCRIPTION DRUG LABEL 1 54868-6304 SOLUTION/ DROPS 0.10 mg OPHTHALMIC NDA 25 sections
Bimatoprost HUMAN PRESCRIPTION DRUG LABEL 1 60219-2149 SOLUTION/ DROPS 0.10 mg OPHTHALMIC ANDA 23 sections
Bimatoprost HUMAN PRESCRIPTION DRUG LABEL 1 60505-0583 SOLUTION/ DROPS 0.30 mg OPHTHALMIC ANDA 24 sections
Bimatoprost Human Prescription Drug Label 1 62332-507 SOLUTION/ DROPS 0.30 mg OPHTHALMIC ANDA 23 sections
bimatoprost Human Prescription Drug Label 1 62332-511 SOLUTION/ DROPS 0.30 mg OPHTHALMIC ANDA 22 sections
Bimatoprost Human Prescription Drug Label 1 65862-802 SOLUTION/ DROPS 0.30 mg OPHTHALMIC ANDA 23 sections
Bimatoprost HUMAN PRESCRIPTION DRUG LABEL 1 68071-3590 SOLUTION/ DROPS 0.30 mg OPHTHALMIC ANDA 23 sections
BIMATOPROST HUMAN PRESCRIPTION DRUG LABEL 1 68071-3612 SOLUTION/ DROPS 0.30 mg OPHTHALMIC ANDA 24 sections
Bimatoprost Human Prescription Drug Label 1 68083-295 SOLUTION/ DROPS 0.30 mg OPHTHALMIC ANDA 23 sections
Bimatoprost Human Prescription Drug Label 1 68083-296 SOLUTION/ DROPS 0.30 mg OPHTHALMIC ANDA 23 sections
Bimatoprost Human Prescription Drug Label 1 68083-439 SOLUTION/ DROPS 0.30 mg OPHTHALMIC ANDA 23 sections
Bimatoprost HUMAN PRESCRIPTION DRUG LABEL 1 70069-401 SOLUTION/ DROPS 0.30 mg OPHTHALMIC ANDA 22 sections
Bimatoprost HUMAN PRESCRIPTION DRUG LABEL 1 70069-402 SOLUTION/ DROPS 0.30 mg OPHTHALMIC ANDA 22 sections
Bimatoprost HUMAN PRESCRIPTION DRUG LABEL 1 70069-403 SOLUTION/ DROPS 0.30 mg OPHTHALMIC ANDA 22 sections
Bimatoprost HUMAN PRESCRIPTION DRUG LABEL 1 70756-626 SOLUTION/ DROPS 0.10 mg OPHTHALMIC ANDA 15 sections
Bimatoprost HUMAN PRESCRIPTION DRUG LABEL 1 70756-627 SOLUTION/ DROPS 0.10 mg OPHTHALMIC ANDA 15 sections
Bimatoprost HUMAN PRESCRIPTION DRUG LABEL 1 70756-628 SOLUTION/ DROPS 0.10 mg OPHTHALMIC ANDA 15 sections
Bimatoprost HUMAN PRESCRIPTION DRUG LABEL 1 72266-139 SOLUTION/ DROPS 0.30 mg OPHTHALMIC ANDA 23 sections